Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hurdles and complexities of codon 13 KRAS mutations.

× No keyword cloud information.

14 in total

1. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.

Authors: Thomas McFall; Jolene K Diedrich; Meron Mengistu; Stacy L Littlechild; Kendra V Paskvan; Laura Sisk-Hackworth; James J Moresco; Andrey S Shaw; Edward C Stites
Journal: Sci Signal Date: 2019-09-24 Impact factor: 8.192

2. Expanded RAS: refining the patient population.

Authors: Chloe E Atreya; Ryan B Corcoran; Scott Kopetz
Journal: J Clin Oncol Date: 2015-01-12 Impact factor: 44.544

3. K-ras oncogene mutation in pterygium.

Authors: B T Ozturk; M S Yıldırım; A Zamani; B Bozkurt
Journal: Eye (Lond) Date: 2016-11-11 Impact factor: 3.775

4. Challenges and strategies for identifying biomarkers for colorectal cancer.

Authors: Bruno Conte; Scott Kopetz
Journal: Colorectal Cancer Date: 2013

5. Intrinsic GTPase Activity of K-RAS Monitored by Native Mass Spectrometry.

Authors: Zahra Moghadamchargari; Jamison Huddleston; Mehdi Shirzadeh; Xueyun Zheng; David E Clemmer; Frank M Raushel; David H Russell; Arthur Laganowsky
Journal: Biochemistry Date: 2019-07-22 Impact factor: 3.162

6. NMR-based functional profiling of RASopathies and oncogenic RAS mutations.

Authors: Matthew J Smith; Benjamin G Neel; Mitsuhiko Ikura
Journal: Proc Natl Acad Sci U S A Date: 2013-03-04 Impact factor: 11.205

Review 7. Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer.

Authors: Siuwah Tang; Jillian Bonaroti; Sebnem Unlu; Xiaoyan Liang; Daolin Tang; Herbert J Zeh; Michael T Lotze
Journal: Pancreas Date: 2013-07 Impact factor: 3.327

8. Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.

Authors: Christian Posch; Martina Sanlorenzo; Igor Vujic; Juan A Oses-Prieto; Brian D Cholewa; Sarasa T Kim; Jeffrey Ma; Kevin Lai; Mitchell Zekhtser; Rosaura Esteve-Puig; Gary Green; Shreya Chand; Alma L Burlingame; Renate Panzer-Grümayer; Klemens Rappersberger; Susana Ortiz-Urda
Journal: J Invest Dermatol Date: 2016-05-29 Impact factor: 8.551

9. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.

Authors: Eva Segelov; Paul Waring; Jayesh Desai; Kate Wilson; Val Gebski; Subotheni Thavaneswaran; Elena Elez; Craig Underhill; Nick Pavlakis; Lorraine Chantrill; Louise Nott; Michael Jefford; Mustafa Khasraw; Fiona Day; Harpreet Wasan; Fortunato Ciardiello; Chris Karapetis; Warren Joubert; Guy van Hazel; Andrew Haydon; Tim Price; Sabine Tejpar; Niall Tebbutt; Jeremy Shapiro
Journal: BMC Cancer Date: 2016-05-31 Impact factor: 4.430

10. Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey.

Authors: J T Park; N Johnson; S Liu; M Levesque; Y J Wang; H Ho; D Huso; A Maitra; M J Parsons; J D Prescott; S D Leach
Journal: Oncogene Date: 2014-07-28 Impact factor: 9.867